Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Hematology

Finding Your Footing After a BPDCN Diagnosis

At a Glance

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare blood cancer that requires care from specialized medical centers. Treatment typically involves targeted therapies like tagraxofusp to reach remission, often followed by a stem cell transplant for the best chance at a long-term cure.

Receiving a diagnosis of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) often feels like being dropped into a foreign world. The name is long, the condition is rare, and the news is heavy. It is completely normal to feel overwhelmed by the “alphabet soup” of this diagnosis [1]. However, even though BPDCN is rare, you are entering a new era of treatment where the path forward is clearer than it has ever been.

Understanding Your Diagnosis

BPDCN is an extremely rare type of blood cancer, with an incidence rate of only about 0.04 cases per 100,000 people [1][2]. It predominantly affects older adults (with a median age at diagnosis between 65 and 70 years) and is significantly more common in men [2][3]. Because it is so uncommon, many local oncologists may never have seen a case in their entire careers [4]. This rarity is why your medical team might seem as surprised as you are; the disease is often misidentified as other types of leukemia or lymphoma before specialized testing confirms it is BPDCN [5][6].

The cancer begins in plasmacytoid dendritic cells (pDCs). In a healthy body, these cells are your immune system’s “first responders” to viral threats [7]. They act like specialized sentries that detect viruses and pump out massive amounts of interferon, a protein that signals the rest of your immune system to wake up and fight [8][9]. In BPDCN, these sentry cells become cancerous and grow uncontrollably [10].

Why Specialized Care Matters

Because BPDCN is complex and rare, it requires a “high-definition” approach to treatment that most community hospitals aren’t equipped to provide [11][4].

  • Expert Diagnosis: Confirming BPDCN requires a specific panel of markers (typically CD123, CD4, and CD56) that requires expert pathologists to interpret correctly [12][6].
  • Multidisciplinary Teams: Your care should ideally involve a team of hematologists, transplant specialists, and dermatologists (since the disease often first appears on the skin) who coordinate your treatment at an academic medical center [13][14].
  • Clinical Experience: Centers that specialize in rare blood cancers have the infrastructure to monitor for specific side effects and provide access to the latest research [15][16].

Three Pillars of Stability

While the diagnosis is aggressive, three key facts can provide a foundation of hope as you begin this journey:

  1. There is a Targeted Therapy: For years, doctors had to use “borrowed” chemotherapy designed for other cancers. Today, there is an FDA-approved drug specifically for BPDCN called tagraxofusp [17][18]. This is a targeted therapy, meaning it is designed to seek out and attach to a specific protein (CD123) found on BPDCN cells [19][20].
  2. Established Protocols for Remission: Doctors now have a clear roadmap. The goal is often to use targeted therapy or intensive chemotherapy to achieve a “deep remission,” which then serves as a “bridge” to a hematopoietic stem cell transplant (HSCT) for eligible patients [19][21]. A transplant offers the highest established probability of a long-term cure [22][23].
  3. Active Research and Innovation: You are not at the end of the road. Beyond the current standard of care, new treatments and clinical trials are constantly evolving, offering more options for patients than were available even five years ago [24][25].

You are your own best advocate. Seeking a second opinion at a center that specializes in BPDCN is not just “extra credit”—it is a standard and recommended step for managing this specific condition [13].

Common questions in this guide

What is blastic plasmacytoid dendritic cell neoplasm (BPDCN)?
BPDCN is an extremely rare and aggressive blood cancer that begins in specialized immune cells called plasmacytoid dendritic cells. Because it is so uncommon, it is often initially misdiagnosed as other types of leukemia or lymphoma.
What is the standard treatment for BPDCN?
Treatment often begins with a targeted therapy drug called tagraxofusp, which seeks out a specific protein called CD123 on the cancer cells. The goal is to achieve a deep remission, which can then act as a bridge to a stem cell transplant.
Should I see a specialist for a BPDCN diagnosis?
Yes, seeking care at an academic medical center that specializes in rare blood cancers is highly recommended. You will need a multidisciplinary team, including hematologists and dermatologists, who have experience treating this rare condition.
What is the role of a stem cell transplant in treating BPDCN?
A hematopoietic stem cell transplant (HSCT) is currently considered the best path to achieving a long-term cure. It is typically performed after targeted therapy or intensive chemotherapy has put the cancer into remission.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many patients with BPDCN have you or this center treated in the last few years?
  2. 2.Do you have a dedicated protocol for monitoring and managing Capillary Leak Syndrome (CLS)?
  3. 3.What is my CD123 expression level, and am I a candidate for targeted therapy with tagraxofusp?
  4. 4.Can we begin the process of HLA typing and searching for a stem cell donor immediately?
  5. 5.Does this center have a multidisciplinary team that includes dermatologists, hematopathologists, and transplant specialists?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Two cases of blastic plasmacytoid dendritic cell neoplasm.

    Hong AS, Alsharabati M, Jagun O, et al.

    International journal of dermatology 2022; (61(10)):e405-e407 doi:10.1111/ijd.16256.

    PMID: 35599304
  2. 2

    Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects.

    Sapienza MR, Pileri A, Derenzini E, et al.

    Cancers 2019; (11(5)) doi:10.3390/cancers11050595.

    PMID: 31035408
  3. 3

    Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report.

    Zheng JX, Betts EV, Dwyre DM, et al.

    Clinical pathology (Thousand Oaks, Ventura County, Calif.) 2024; (17()):2632010X241304564 doi:10.1177/2632010X241304564.

    PMID: 39687328
  4. 4

    Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.

    Pemmaraju N, Madanat YF, Rizzieri D, et al.

    Leukemia & lymphoma 2024; (65(5)):548-559 doi:10.1080/10428194.2024.2305288.

    PMID: 38391126
  5. 5

    Blastic plasmacytoid dendritic cell neoplasm with response to pralatrexate.

    Sato S, Tanaka E, Tamai Y

    Annals of hematology 2019; (98(3)):801-803 doi:10.1007/s00277-019-03611-3.

    PMID: 30652209
  6. 6

    Diagnostic approach to blastic plasmacytoid dendritic cell neoplasm: historical perspectives and current understanding.

    Sakamoto K, Takeuchi K

    Journal of clinical and experimental hematopathology : JCEH 2025; (65(1)):1-16 doi:10.3960/jslrt.24069.

    PMID: 40159280
  7. 7

    SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4.

    Onodi F, Bonnet-Madin L, Meertens L, et al.

    The Journal of experimental medicine 2021; (218(4)) doi:10.1084/jem.20201387.

    PMID: 33533916
  8. 8

    Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors.

    Villani AC, Satija R, Reynolds G, et al.

    Science (New York, N.Y.) 2017; (356(6335)) doi:10.1126/science.aah4573.

    PMID: 28428369
  9. 9

    Human genetic and immunological determinants of critical COVID-19 pneumonia.

    Zhang Q, Bastard P, , et al.

    Nature 2022; (603(7902)):587-598 doi:10.1038/s41586-022-04447-0.

    PMID: 35090163
  10. 10

    Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. A single-case report.

    Iversen KF, Holdgaard PC, Preiss B, et al.

    Haematologica 2019; (104(9)):e432-e433 doi:10.3324/haematol.2018.214635.

    PMID: 30975908
  11. 11

    The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm.

    Marmouset V, Joris M, Merlusca L, et al.

    Hematological oncology 2019; (37(4)):487-489 doi:10.1002/hon.2671.

    PMID: 31465531
  12. 12

    Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm.

    Wang W, Khoury JD, Miranda RN, et al.

    Haematologica 2021; (106(4)):1047-1055 doi:10.3324/haematol.2020.247569.

    PMID: 32241840
  13. 13

    North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.

    Pemmaraju N, Kantarjian H, Sweet K, et al.

    Blood 2023; (141(6)):567-578 doi:10.1182/blood.2022017865.

    PMID: 36399715
  14. 14

    Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base.

    Krah NM, Hoeg R, Shami PJ, et al.

    Leukemia research reports 2025; (24()):100541 doi:10.1016/j.lrr.2025.100541.

    PMID: 40917153
  15. 15

    Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.

    Economides MP, Konopleva M, Pemmaraju N

    Therapeutic advances in hematology 2019; (10()):2040620719874733 doi:10.1177/2040620719874733.

    PMID: 31579499
  16. 16

    Targeting CD123 in BPDCN: an emerging field.

    DiPippo AJ, Wilson NR, Pemmaraju N

    Expert review of hematology 2021; (14(11)):993-1004 doi:10.1080/17474086.2021.1988848.

    PMID: 34607517
  17. 17

    Blastic plasmacytoid dendritic cell neoplasm: diagnosis, manifestations, and treatment.

    Sweet K

    Current opinion in hematology 2020; (27(2)):103-107 doi:10.1097/MOH.0000000000000569.

    PMID: 31972688
  18. 18

    Blastic Plasmacytoid Dendritic Cell Neoplasm.

    Jain A, Sweet K

    Journal of the National Comprehensive Cancer Network : JNCCN 2023; (21(5)):515-521 doi:10.6004/jnccn.2023.7026.

    PMID: 37156483
  19. 19

    Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN).

    Alfayez M, Konopleva M, Pemmaraju N

    Expert opinion on biological therapy 2020; (20(2)):115-123 doi:10.1080/14712598.2020.1701651.

    PMID: 31801379
  20. 20

    Durable outcomes with manageable safety leading to prolonged survival with tagraxofusp for treatment-naïve patients with blastic plasmacytoid dendritic cell neoplasm: real world results from a European Named Patient Program.

    Herling M, Angelucci E, Benoit TM, et al.

    Annals of hematology 2025; (104(8)):4121-4131 doi:10.1007/s00277-025-06493-w.

    PMID: 40751756
  21. 21

    Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.

    Lee SS, McCue D, Pemmaraju N

    Expert review of anticancer therapy 2020; (20(7)):543-550 doi:10.1080/14737140.2020.1776120.

    PMID: 32460559
  22. 22

    Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant.

    Yun S, Chan O, Kerr D, et al.

    Blood advances 2020; (4(14)):3435-3442 doi:10.1182/bloodadvances.2020001875.

    PMID: 32722779
  23. 23

    Real-world evidence on tagraxofusp for blastic plasmacytoid dendritic cell neoplasm - collected cases from a single center and case reports.

    Faustmann P, Schroeder JC, Mix L, et al.

    Frontiers in oncology 2024; (14()):1384172 doi:10.3389/fonc.2024.1384172.

    PMID: 38665943
  24. 24

    The advances in therapy of blastic plasmacytoid dendritic cell neoplasm.

    Kerr D, Sokol L

    Expert opinion on investigational drugs 2018; (27(9)):733-739 doi:10.1080/13543784.2018.1512970.

    PMID: 30118336
  25. 25

    Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients.

    Laribi K, Baugier de Materre A, Sobh M, et al.

    Blood advances 2020; (4(19)):4838-4848 doi:10.1182/bloodadvances.2020002474.

    PMID: 33027528

This page provides educational information about BPDCN diagnosis and general treatment paths. It is not medical advice. Always consult your oncology and hematology team for decisions about your specific care.

Get notified when new evidence is published on Blastic plasmacytoid dendritic cell neoplasm.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.